Press Releases

November 13, 2020

Regulatory

SynAct Pharma publishes Q3 2020 interim report (in Swedish)

November 9, 2020

Regulatory

SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis

November 6, 2020

Regulatory

Bulletin from the extraordinary shareholders’ meeting in SynAct Pharma AB

October 20, 2020

Regulatory

Notice of extraordinary shareholders’ meeting in SynAct Pharma AB

October 20, 2020

Regulatory

Shareholders of SynAct Pharma proposes Uli Hacksell as new board member

October 19, 2020

Regulatory

SynAct Pharma terminates agreement for liquidity providing

October 12, 2020

Regulatory

English version of PR published 20201012 at 07.33AM     SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis

September 23, 2020

Regulatory

Swedish version of press release published earlier today. SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter

September 23, 2020

Regulatory

SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients

September 3, 2020

Regulatory

SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed

September 1, 2020

Regulatory

SynAct Pharma Informs about Termination of Coverage Agreement with Redeye

August 28, 2020

Regulatory

SynAct Pharma publishes Q2 2020 interim report (in Swedish)

August 28, 2020

Regulatory

SynAct Pharma Initiates RESOVIR: Scientific and clinical Collaboration to Explore AP1189 in Viral Infections

July 27, 2020

Regulatory

Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4

July 15, 2020

Regulatory

SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis

June 30, 2020

Regulatory

SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020

June 29, 2020

Regulatory

SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome

June 25, 2020

Regulatory

SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2

June 2, 2020

Regulatory

SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency

May 25, 2020

Regulatory

SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases

May 5, 2020

Regulatory

SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression

May 5, 2020

Regulatory

SynAct Pharma publishes Q1 2020 interim report (in Swedish)

April 3, 2020

Regulatory

SynAct Pharma applies for patent for AP1189 within COVID-19

April 2, 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)

March 31, 2020

Regulatory

SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome

March 31, 2020

Regulatory

Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19

February 11, 2020

Regulatory

SynAct Pharma publishes Annual Results for 2019 (in Swedish)